These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21919608)

  • 41. Tumor priming enhances delivery and efficacy of nanomedicines.
    Lu D; Wientjes MG; Lu Z; Au JL
    J Pharmacol Exp Ther; 2007 Jul; 322(1):80-8. PubMed ID: 17420296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance.
    Xiao H; Song H; Yang Q; Cai H; Qi R; Yan L; Liu S; Zheng Y; Huang Y; Liu T; Jing X
    Biomaterials; 2012 Sep; 33(27):6507-19. PubMed ID: 22727463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer chronotherapeutics: experimental, theoretical, and clinical aspects.
    Ortiz-Tudela E; Mteyrek A; Ballesta A; Innominato PF; Lévi F
    Handb Exp Pharmacol; 2013; (217):261-88. PubMed ID: 23604483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
    Kalbakis K; Pappas P; Kouroussis C; Vamvakas L; Kalykaki A; Vardakis N; Nikolaidou M; Marselos M; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):449-56. PubMed ID: 17960381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A model of competing saturable kinetic processes with application to the pharmacokinetics of the anticancer drug paclitaxel.
    Marsh RE; Tuszyński JA; Sawyer M; Vos KJ
    Math Biosci Eng; 2011 Apr; 8(2):325-54. PubMed ID: 21631133
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The polyamine transport system as a target for anticancer drug development.
    Palmer AJ; Wallace HM
    Amino Acids; 2010 Feb; 38(2):415-22. PubMed ID: 19956998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Computational modeling to predict effect of treatment schedule on drug delivery to prostate in humans.
    Hu L; Au JL; Wientjes MG
    Clin Cancer Res; 2007 Feb; 13(4):1278-87. PubMed ID: 17317840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ultrastructural changes in tumor cells treated with liposomal forms of anticancer drugs.
    Yurchenko OV; Rusetskya NV; Naleskina LA; Chekhun VF
    Exp Oncol; 2010 Mar; 32(1):23-8. PubMed ID: 20332761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
    Mayer LD; Dougherty G; Harasym TO; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Theoretical models for drug delivery to solid tumors.
    el-Kareh AW; Secomb TW
    Crit Rev Biomed Eng; 1997; 25(6):503-71. PubMed ID: 9719859
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biochemical pathway modeling tools for drug target detection in cancer and other complex diseases.
    Marin-Sanguino A; Gupta SK; Voit EO; Vera J
    Methods Enzymol; 2011; 487():319-69. PubMed ID: 21187230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting oncogenic signaling pathways by exploiting nanotechnology.
    Basu S; Chaudhuri P; Sengupta S
    Cell Cycle; 2009 Nov; 8(21):3480-7. PubMed ID: 19823014
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mathematical modelling of drug transport and uptake in a realistic model of solid tumour.
    Zhan W; Gedroyc W; Xu XY
    Protein Pept Lett; 2014; 21(11):1146-56. PubMed ID: 25106906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transport of drugs from blood vessels to tumour tissue.
    Dewhirst MW; Secomb TW
    Nat Rev Cancer; 2017 Dec; 17(12):738-750. PubMed ID: 29123246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling.
    Karolak A; Estrella VC; Huynh AS; Chen T; Vagner J; Morse DL; Rejniak KA
    Sci Rep; 2018 Feb; 8(1):3638. PubMed ID: 29483578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Application of nanomedical approaches in experimental and clinical oncology.
    Torchilin VP
    Anticancer Agents Med Chem; 2006 Nov; 6(6):501. PubMed ID: 17100554
    [No Abstract]   [Full Text] [Related]  

  • 57. Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review.
    Nijenhuis CM; Schellens JH; Beijnen JH
    Drug Metab Rev; 2016 May; 48(2):266-80. PubMed ID: 27186889
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors.
    van de Ven AL; Wu M; Lowengrub J; McDougall SR; Chaplain MA; Cristini V; Ferrari M; Frieboes HB
    AIP Adv; 2012 Mar; 2(1):11208. PubMed ID: 22489278
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mathematical modeling of controlled drug delivery.
    Siepmann J; Peppas NA
    Adv Drug Deliv Rev; 2001 Jun; 48(2-3):137-8. PubMed ID: 11369078
    [No Abstract]   [Full Text] [Related]  

  • 60. Resistance Development: A Major Piece in the Jigsaw Puzzle of Tumor Size Modeling.
    Terranova N; Girard P; Klinkhardt U; Munafo A
    CPT Pharmacometrics Syst Pharmacol; 2015 Jun; 4(6):320-3. PubMed ID: 26225260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.